Close menu

February 24th, 2022 | 11:30 CET

SYNLAB, XPhyto, Novavax - How long will the Corona boom last?

  • Biotechnology
Photo credits:

Corona has been turning the world upside down for two years. Although the stock markets have largely recovered from their crash in February and March 2020 and are clearly up again, some stocks are still doing much better, thanks to Corona. For example, shares of companies involved in developing and producing Corona vaccines, medicines, or testing methods have significantly outperformed the indices. But how sustainable is this boom?

time to read: 3 minutes | Author: Carsten Mainitz

Table of contents:

    SYNLAB - High sales thanks to increased PCR and antigen tests

    One beneficiary of the Corona Crisis is the German laboratory services provider SYNLAB. The Munich-based Company had only sought its way onto the stock exchange floor at the end of April 2021, after achieving sales of EUR 2.2 billion in 2020. According to an estimate by rating agency Fitch, overall sales growth in that year, which was solely attributable to the Corona pandemic, was around 30%. With the IPO, in which over EUR 770 million was placed, the Company raised around EUR 400 million through the issue of new shares.

    According to analysts at Deutsche Bank, the Bavarians achieved sales of around EUR 190 million in January 2022. At the same time, the original plans for the full year envisaged sales of EUR 500 million. Even if the test volume should decrease again in the coming months, it can thus be assumed that the sales forecast will be exceeded. Deutsche Bank increased its price target to EUR 27. Nevertheless, the market was relatively unimpressed and sent the stock towards the issue price of EUR 18 in the wake of the negative stock market sentiment. For long-term oriented investors, these are good entry opportunities.

    XPhyto Therapeutics - Is the 25-minute PCR test a blockbuster?

    The German-Canadian bio-accelerator XPhyto Therapeutics Corp. is also a beneficiary of the Corona Crisis. In addition to its two mainstays of "psychedelic active ingredients" and "innovative dosage forms," the diversified Company has developed a rapid PCR test that delivers a reliable result within 25 minutes - without the need to send the samples to a laboratory. This rapid PCR test is suitable for all applications where a result with the speed of an antigen test but with the certainty of a PCR test is desirable, such as at airports, on cruise ships or for visitors to highly sensitive areas such as hospitals or nursing homes.

    Following the approval of the rapid test procedure in December, XPhyto has strongly concentrated its sales activities given the market potential here. For example, Drahoslav Zdarek, who was previously responsible for marketing and sales within Europe at Israel's Teva Pharmaceutical for 13 years, was hired as sales manager for the continent. In addition, the first distribution agreements were concluded - with the Company digitallifecare GmbH, an operator of Corona test centers, and a pharmacy association in southern Germany. All this is supported by the new Head of Business Development, Roland Spiess, who was previously responsible for annual sales of EUR 200 million as Chief Financial Officer of Wörwag Pharma.

    The Company is also stepping on the gas internationally. In January, a distribution agreement was signed with TechUnit s.r.o. to launch the PCR rapid test on the Czech market. In a second step, the Company will then take care of further marketing in Slovakia, Ukraine and Russia.

    Novavax - Celebratory mood

    When one thinks of successful stocks in the wake of the Corona pandemic, BioNTech comes to mind. But, the share of Novavax, the US vaccine developer, has fared much better in percentage terms, even though the Company can only deliver its first vaccine doses now. Thus, the stock has increased tenfold from around USD 9.50 in March 2020 to currently USD 95, while BioNTech's shares have "only" quadrupled from around USD 40 to USD 160 in the same period.

    Despite the good news from BioNTech on current tests with the Omicron variant of the coronavirus and the prospect of the imminent delivery of a specially adapted vaccine, the Mainz-based Company is currently having a difficult time on the stock market. Novavax, on the other hand, is benefiting from the fact that its vaccine, Nuvaxovid, can finally be delivered. Many see it as a "miracle cure" for those who have so far refrained from vaccination for fear of the novel mRNA technology or vector vaccines.

    But Nuvaxovid is a "wonder drug" even for Novavax: the Company has never before managed to develop a finished active ingredient in its more than thirty-year history. Jeffries analysts see great potential for the vaccine. They point to its advantageous clinical profile and to the commitments made so far to purchase around 1.7 billion doses. The analysts' recommendation is a 'Buy' with a price target of USD 198.

    The pandemic is evolving into an endemic, but there is still a long way to go before it ends. Reaching people who have so far rejected vaccinations and fast, reliable testing methods will remain important goals in the near future. In this respect, the Novavax and XPhyto papers are certainly interesting at this stage. Given the PCR rapid test's great potential and because of XPhyto's other mainstays, we see great opportunities. SYNLAB also offers a favorable entry opportunity.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

    Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

    • Biotechnology
    • Pharma

    The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.


    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.


    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.